Biodesix (BDSX) to Release Earnings on Thursday

Biodesix (NASDAQ:BDSX) is expected to issue its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect the company to announce earnings of ($1.05) per share and revenue of $26.25 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:30 PM ET.

Biodesix Stock Up 2.0%

Biodesix stock opened at $13.02 on Wednesday. The stock’s 50 day moving average price is $9.12 and its 200 day moving average price is $8.24. Biodesix has a 1-year low of $3.44 and a 1-year high of $19.13. The company has a market cap of $103.59 million, a PE ratio of -2.34 and a beta of 0.66. The company has a debt-to-equity ratio of 41.11, a current ratio of 1.84 and a quick ratio of 1.84.

Insider Buying and Selling at Biodesix

In related news, CEO Scott Hutton sold 3,559 shares of the business’s stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $10.08, for a total value of $35,874.72. Following the sale, the chief executive officer directly owned 45,413 shares in the company, valued at $457,763.04. The trade was a 7.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jack W. Schuler acquired 82,465 shares of the stock in a transaction that occurred on Thursday, January 22nd. The stock was acquired at an average cost of $10.96 per share, for a total transaction of $903,816.40. Following the completion of the purchase, the director owned 1,463,210 shares in the company, valued at $16,036,781.60. The trade was a 5.97% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have bought 182,465 shares of company stock valued at $2,084,616 and have sold 10,999 shares valued at $116,095. Insiders own 30.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. XTX Topco Ltd raised its position in shares of Biodesix by 99.4% during the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after purchasing an additional 102,494 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Biodesix by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock worth $289,000 after acquiring an additional 2,235 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of Biodesix in the fourth quarter valued at $187,000. State Street Corp lifted its position in shares of Biodesix by 15.6% in the fourth quarter. State Street Corp now owns 17,802 shares of the company’s stock valued at $121,000 after acquiring an additional 2,400 shares in the last quarter. Finally, DRW Securities LLC acquired a new stake in shares of Biodesix during the fourth quarter valued at $105,000. 20.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Biodesix in a research report on Monday, December 22nd. Canaccord Genuity Group reiterated a “buy” rating and issued a $20.00 price objective on shares of Biodesix in a research note on Tuesday, February 17th. Finally, Wall Street Zen raised shares of Biodesix from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $32.50.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.